Therapeutic cancer vaccines and combination immunotherapies involving vaccination

References

• SiegelRNaishadhamDJemalACancer statistics, 2013CA Cancer Clin20136311130
   PubMed Web of Science ®Google Scholar
• NautsHCSwiftWEColeyBLThe treatment of malignant tumors by bacterial toxins as developed by the late Coley WB, reviewed in the light of modern researchCancer Res19466420521621018724
   PubMed Web of Science ®Google Scholar
• PaluckaKBanchereauJCancer immunotherapy via dendritic cellsNat Rev Cancer201212426527722437871
   PubMed Web of Science ®Google Scholar
• ChenDSMellmanIOncology meets immunology: the cancer-immunity cycleImmunity201339111023890059
   PubMed Web of Science ®Google Scholar
• BlattmanJNGreenbergPDCancer immunotherapy: a treatment for the massesScience2004305568120020515247469
   PubMed Web of Science ®Google Scholar
• HamidORobertCDaudASafety and tumor responses with lambrolizumab (anti-PD-1) in melanomaN Engl J Med2013369213414423724846
   PubMed Web of Science ®Google Scholar
• WolchokJDKlugerHCallahanMKNivolumab plus ipilimumab in advanced melanomaN Engl J Med2013369212213323724867
   PubMed Web of Science ®Google Scholar
• VacchelliEGalluzziLEggermontATrial watch: FDA-approved Toll-like receptor agonists for cancer therapyOncoimmunology20121689490723162757
   PubMed Web of Science ®Google Scholar
• EggermontAMSuciuSTestoriALong-term results of the randomized phase III Trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanomaJ Clin Oncol201230313810381823008300
   PubMed Web of Science ®Google Scholar
• ClementJMMcDermottDFThe high-dose aldesleukin (IL-2) “SELECT” trial: a trial designed to prospectively validate predictive models of response to high-dose IL-2 treatment in patients with metastatic renal cell carcinomaClin Genitourin Cancer200972E7E919692326
   PubMed Web of Science ®Google Scholar
• LipsonEJDrakeCGIpilimumab: an anti-CTLA-4 antibody for metastatic melanomaClin Cancer Res201117226958696221900389
   PubMed Web of Science ®Google Scholar
• GoldmanBDeFrancescoLThe cancer vaccine roller coasterNat Biotechnol200927212913919204689
   PubMed Web of Science ®Google Scholar
• RiceJOttensmeierCHStevensonFKDNA vaccines: precision tools for activating effective immunity against cancerNat Rev Cancer20088210812018219306
   PubMed Web of Science ®Google Scholar
• LaroccaCSchlomJViral vector-based therapeutic cancer vaccinesCancer J201117535937121952287
   PubMed Web of Science ®Google Scholar
• BartlettDLLiuZSathaiahMOncolytic viruses as therapeutic cancer vaccinesMol Cancer201312110324020520
   PubMed Web of Science ®Google Scholar
• MockeyMBourseauEChandrashekharVmRNA-based cancer vaccine: prevention of B16 melanoma progression and metastasis by systemic injection of MART1 mRNA histidylated lipopolyplexesCancer Gene Ther200714980281417589432
   PubMed Web of Science ®Google Scholar
• DikenMKreiterSSelmiATureciOSahinUAntitumor vaccination with synthetic mRNA: strategies for in vitro and in vivo preclinical studiesMethods Mol Biol201396923524623296938
   PubMedGoogle Scholar
• Fotin-MleczekMDuchardtKMLorenzCMessenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activityJ Immunother201134111521150709
   PubMed Web of Science ®Google Scholar
• Heimburg-MolinaroJLumMVijayGJainMAlmogrenARittenhouse-OlsonKCancer vaccines and carbohydrate epitopesVaccine201129488802882621964054
   PubMed Web of Science ®Google Scholar
• AlmandBResserJRLindmanBClinical significance of defective dendritic cell differentiation in cancerClin Cancer J20006517551766
   PubMed Web of Science ®Google Scholar
• Della BellaSGennaroMVaccariMAltered maturation of peripheral blood dendritic cells in patients with breast cancerBr J Cancer20038981463147214562018
   PubMed Web of Science ®Google Scholar
• ObermajerNMuthuswamyRLesnockJEdwardsRPKalinskiPPositive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cellsBlood2011118205498550521972293
   PubMed Web of Science ®Google Scholar
• ObermajerNKalinskiPKey role of the positive feedback between PGE(2) and COX2 in the biology of myeloid-derived suppressor cellsOncoimmunology20121576276422934275
   PubMed Web of Science ®Google Scholar
• NakamuraYWatchmakerPUrbanJHelper function of memory CD8+ T cells: heterologous CD8+ T cells support the induction of therapeutic cancer immunityCancer Res20076720100121001817942935
   PubMed Web of Science ®Google Scholar
• WatchmakerPBUrbanJABerkEMemory CD8+ T cells protect dendritic cells from CTL killingJ Immunol200818063857386518322193
   PubMed Web of Science ®Google Scholar
• CooperAMKhaderSAThe role of cytokines in the initiation, expansion, and control of cellular immunity to tuberculosisImmunol Rev200822619120419161425
   PubMed Web of Science ®Google Scholar
• HaringJSBadovinacVPHartyJTInflaming the CD8+ T cell responseImmunity2006251192916860754
   PubMed Web of Science ®Google Scholar
• KalinskiPOkadaHPolarized dendritic cells as cancer vaccines: directing effector-type T cells to tumorsSemin Immunol201022317318220409732
   PubMed Web of Science ®Google Scholar
• HartlDKrauss-EtschmannSKollerBInfiltrated neutrophils acquire novel chemokine receptor expression and chemokine responsiveness in chronic inflammatory lung diseasesJ Immunol2008181118053806719017998
   PubMed Web of Science ®Google Scholar
• ZouWRegulatory T cells, tumour immunity and immunotherapyNat Rev Immunol20066429530716557261
   PubMed Web of Science ®Google Scholar
• CurielTJCoukosGZouLSpecific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survivalNat Med200410994294915322536
   PubMed Web of Science ®Google Scholar
• MuthuswamyRBerkEJuneckoBFNF-kappaB hyperactivation in tumor tissues allows tumor-selective reprogramming of the chemokine microenvironment to enhance the recruitment of cytolytic T effector cellsCancer Res201272153735374322593190
   PubMed Web of Science ®Google Scholar
• ZouWMachelonVCoulomb-L’HerminAStromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cellsNat Med20017121339134611726975
   PubMed Web of Science ®Google Scholar
• ObermajerNMuthuswamyROdunsiKEdwardsRPKalinskiPPGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environmentCancer Res201171247463747022025564
   PubMed Web of Science ®Google Scholar
• KryczekIWeiSKellerELiuRZouWStroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesisAm J Physiol Cell Physiol20072923C987C99516943240
   PubMed Web of Science ®Google Scholar
• MeliefCJCancer immunotherapy by dendritic cellsImmunity200829337238318799145
   PubMed Web of Science ®Google Scholar
• RabinovichGAGabrilovichDSotomayorEMImmunosuppressive strategies that are mediated by tumor cellsAnnu Rev Immunol20072526729617134371
   PubMed Web of Science ®Google Scholar
• UchidaKSchneiderSYochimJMIntratumoral COX-2 gene expression is a predictive factor for colorectal cancer response to fluoropyrimidine-based chemotherapyClin Cancer Res20051193363336815867236
   PubMed Web of Science ®Google Scholar
• BanerjeeDKDhodapkarMVMatayevaESteinmanRMDhodapkarKMExpansion of FOXP3 high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patientsBlood200610882655266116763205
   PubMed Web of Science ®Google Scholar
• ViewegJSuZDahmPKusmartsevSReversal of tumor-mediated immunosuppressionClin Cancer Res2007132 Pt 2727s732s17255301
   PubMed Web of Science ®Google Scholar
• SheikhNAPetrylakDKantoffPWSipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancerCancer Immunol Immunother201362113714722865266
   PubMed Web of Science ®Google Scholar
• CheeverMAHiganoCSProvenge (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccineClin Cancer Res201117113520352621471425
   PubMed Web of Science ®Google Scholar
• KantoffPWHiganoCSShoreNDSipuleucel-T immunotherapy for castration-resistant prostate cancerN Engl J Med2010363541142220818862
   PubMed Web of Science ®Google Scholar
• HiganoCSSchellhammerPFSmallEJIntegrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancerCancer2009115163670367919536890
   PubMed Web of Science ®Google Scholar
• ClinicalTrialsgovNational Institutes of HealthBethesda, MD, USA Available from: http://www.ClinicalTrials.govAccessed November 28, 2013
   Google Scholar
• HodiFSO’DaySJMcDermottDFImproved survival with ipilimumab in patients with metastatic melanomaN Engl J Med2010363871172320525992
   PubMed Web of Science ®Google Scholar
• SchwartzentruberDJLawsonDHRichardsJMgp100 peptide vaccine and interleukin-2 in patients with advanced melanomaN Engl J Med2011364222119212721631324
   PubMed Web of Science ®Google Scholar
• MiddletonGWValleJWWadsleyJA phase III randomized trial of chemoimmunotherapy comprising gemcitabine and capecitabine with or without telomerase vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancerJ Clin Oncol201331Suppl 15 Abstr LBA4004
   Web of Science ®Google Scholar
• QuoixERamlauRWesteelVTherapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trialLancet Oncol201112121125113322019520
   PubMed Web of Science ®Google Scholar
• HardacreJMMulcahyMSmallWAddition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 studyJ Gastrointest Surg20131719410023229886
   PubMed Web of Science ®Google Scholar
• MorrisJCRossiGRHaroldNPotential chemo-sensitization effect of tergenpumatucel-L immunotherapy in treated patients with advanced non-small cell lung cancer (NSCLC)J Clin Oncol201331Suppl 15 Abstr 8094
   Web of Science ®Google Scholar
• BandmanODelcayreALausRPROSPECT: A randomized, double-blind, phase III efficacy trial of PROSTVACJ Clin Oncol201230Suppl 15 Abstr TPS4699
   Web of Science ®Google Scholar
• GiacconeGBazhenovaLNemunaitisJA phase III study of belagenpumatucel-L therapeutic tumor cell vaccine for non-small cell lung cancer (NSCLC) Available from: http://eccamsterdam2013.ecco-org.eu/Scientific-Programme/Abstract-search.aspx?abstractid=8961Accessed November 28, 2013
   Google Scholar
• ButtsCSocinskiMAMitchellPLTecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trialLancet Oncol2014151596824331154
   PubMed Web of Science ®Google Scholar
• LawsonDHLeeSJTarhiniAAMargolinKAErnstoffMSKirkwoodJME4697: Phase III cooperative group study of yeast-derived granulocyte macrophage colony-stimulating factor (GM-CSF) versus placebo as adjuvant treatment of patients with completely resected stage III–IV melanomaJ Clin Oncol201028Suppl 15 Abstr 8504
   Web of Science ®Google Scholar
• WalterSWeinschenkTStenzlAMultipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survivalNat Med20121881254126122842478
   PubMed Web of Science ®Google Scholar
• TherassePVansteenkisteJFZielinskiMMAGRIT phase III trial: MAGE-A3 antigen-specific cancer immunotherapy (ASCI) as adjuvant therapy in patients with completely resected stage IB-IIIA NSCLCJ Clin Oncol201129Suppl 15 Abstr TPS210
   Web of Science ®Google Scholar
• GlaxoSmithKlineThe investigational MAGE-A3 antigen-specific cancer immunotherapeutic does not meet first co-primary endpoint in Phase III melanoma clinical trial2013 Available from: http://www.gsk.com/media/press-releases/2013/the-investigational-mage-a3-antigen-specific-cancer-immunotherap.htmlAccessed January 14, 2014
   Google Scholar
• GlaxoSmithKlineUpdate on phase III clinical trial of investigational MAGE-A3 antigen-specific cancer immunotherapeutic in non-small cell lung cancer2014 Available from: http://www.gsk.com/media/press-releases/2014/update-on-phase-III-clinical-trial-of-investigational-MAGE-A3-antigen-specific-cancer-immunotherapeutic-in-non-small-cell-lung-cancer.htmlAccessed June 19, 2014
   Google Scholar
• Ulloa-MontoyaFLouahedJDizierBPredictive gene signature in MAGE-A3 antigen-specific cancer immunotherapyJ Clin Oncol201331192388239523715562
   PubMed Web of Science ®Google Scholar
• VansteenkisteJZielinskiMLinderAAdjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study resultsJ Clin Oncol201331192396240323715567
   PubMed Web of Science ®Google Scholar
• MortonDLMozzilloNThompsonJFAn international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sitesJ Clin Oncol200725Suppl 18 Abstr 8508
   Web of Science ®Google Scholar
• HoshimotoSFariesMBMortonDLAssessment of prognostic circulating tumor cells in a phase III trial of adjuvant immunotherapy after complete resection of stage IV melanomaAnn Surg2012255235736222202581
   PubMed Web of Science ®Google Scholar
• EggermontAMSuciuSRutkowskiPAdjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor .1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trialJ Clin Oncol201331303831383724019551
   PubMed Web of Science ®Google Scholar
• GulleyJLMadanRASchlomJImpact of tumour volume on the potential efficacy of therapeutic vaccinesCurr Oncol2011183e150e15721655153
   PubMed Web of Science ®Google Scholar
• SchlomJTherapeutic cancer vaccines: current status and moving forwardJ Natl Cancer Inst2012104859961322395641
   PubMed Web of Science ®Google Scholar
• WolchokJDHoosAO’DaySGuidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteriaClin Cancer Res200915237412742019934295
   PubMed Web of Science ®Google Scholar
• SchlomJArlenPMGulleyJLCancer vaccines: moving beyond current paradigmsClin Cancer Res200713133776378217606707
   PubMed Web of Science ®Google Scholar
• BilusicMGulleyJLEndpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccinesCancer Immunol Immunother201261110911722120693
   PubMed Web of Science ®Google Scholar
• HarropRTreasurePde BelinJAnalysis of pre-treatment markers predictive of treatment benefit for the therapeutic cancer vaccine MVA-5T4 (TroVax)Cancer Immunol Immunother201261122283229422692758
   PubMed Web of Science ®Google Scholar
• SkachkovaOVKhranovskaNMGorbachOISvergunNMSydorRINikulinaVVImmunological markers of anti-tumor dendritic cells vaccine efficiency in patients with non-small cell lung cancerExp Oncol201335210911323828386
   PubMedGoogle Scholar
• CornforthANLeeGJFowlerAWCarbonellDJDillmanROIncreases in serum TARC/CCL17 levels are associated with progression-free survival in advanced melanoma patients in response to dendritic cell-based immunotherapyJ Clin Immunol200929565766419421847
   PubMed Web of Science ®Google Scholar
• LopezMNPeredaCSegalGProlonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cellsJ Clin Oncol200927694595219139436
   PubMed Web of Science ®Google Scholar
• OkadaHKalinskiPUedaRInduction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant gliomaJ Clin Oncol201129333033621149657
   PubMed Web of Science ®Google Scholar
• CarrenoBMBecker-HapakMHuangAIL-12p70-producing patient DC vaccine elicits Tc1-polarized immunityJ Clin Invest201312383383339423867552
   PubMed Web of Science ®Google Scholar
• PaluckaKUenoHBanchereauJRecent developments in cancer vaccinesJ Immunol201118631325133121248270
   PubMed Web of Science ®Google Scholar
• HerberDLCaoWNefedovaYLipid accumulation and dendritic cell dysfunction in cancerNat Med201016888088620622859
   PubMed Web of Science ®Google Scholar
• Pinzon-CharryAMaxwellTLopezJADendritic cell dysfunction in cancer: a mechanism for immunosuppressionImmunol Cell Biol200583545146116174093
   PubMed Web of Science ®Google Scholar
• DillmanROCornforthANDepriestCTumor stem cell antigens as consolidative active specific immunotherapy: a randomized phase II trial of dendritic cells versus tumor cells in patients with metastatic melanomaJ Immunother201235864164922996370
   PubMed Web of Science ®Google Scholar
• KalinskiPDendritic cells in immunotherapy of established cancer: roles of signals 1, 2, 3 and 4Curr Opin Investig Drugs2009106526535
   PubMedGoogle Scholar
• BanchereauJSteinmanRMDendritic cells and the control of immunityNature199839266732452529521319
   PubMed Web of Science ®Google Scholar
• ChiangCLKandalaftLETanyiJA dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedsideClin Cancer Res201319174801481523838316
   PubMed Web of Science ®Google Scholar
• ReyesDSalazarLEspinozaETumour cell lysate-loaded dendritic cell vaccine induces biochemical and memory immune response in castration-resistant prostate cancer patientsBr J Cancer201310961488149723989944
   PubMed Web of Science ®Google Scholar
• StromeSEVossSWilcoxRStrategies for antigen loading of dendritic cells to enhance the antitumor immune responseCancer Res20026261884188911912169
   PubMed Web of Science ®Google Scholar
• AlbertMLSauterBBhardwajNDendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLsNature1998392667186899510252
   PubMed Web of Science ®Google Scholar
• KalinskiPMuthuswamyRUrbanJDendritic cells in cancer immunotherapy: vaccines and combination immunotherapiesExp Rev Vaccines2013123285295
   PubMed Web of Science ®Google Scholar
• AndersenBMOhlfestJRIncreasing the efficacy of tumor cell vaccines by enhancing cross primingCancer Lett2012325215516422809568
   PubMed Web of Science ®Google Scholar
• GrakouiABromleySKSumenCThe immunological synapse: a molecular machine controlling T cell activationScience1999285542522122710398592
   PubMed Web of Science ®Google Scholar
• HawigerDInabaKDorsettYDendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivoJ Exp Med2001194676977911560993
   PubMed Web of Science ®Google Scholar
• de VriesIJLesterhuisWJScharenborgNMMaturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patientsClin Cancer Res20039145091510014613986
   PubMed Web of Science ®Google Scholar
• AdemaGJde VriesIJPuntCJFigdorCGMigration of dendritic cell based cancer vaccines: in vivo veritas?Curr Opin Immunol200517217017415766677
   PubMed Web of Science ®Google Scholar
• ReddyASappMFeldmanMSubkleweMBhardwajNA monocyte conditioned medium is more effective than defined cytokines in mediating the terminal maturation of human dendritic cellsBlood1997909364036469345048
   PubMed Web of Science ®Google Scholar
• JonuleitHKuhnUMullerGPro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditionsEur J Immunol19972712313531429464798
   PubMed Web of Science ®Google Scholar
• SchadendorfDUgurelSSchuler-ThurnerBDacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOGAnn Oncol200617456357016418308
   PubMed Web of Science ®Google Scholar
• KalinskiPHilkensCMWierengaEAKapsenbergMLT-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signalImmunol Today1999201256156710562707
   PubMedGoogle Scholar
• KalinskiPRegulation of immune responses by prostaglandin E2J Immunol20121881212822187483
   PubMed Web of Science ®Google Scholar
• WatchmakerPBBerkEMuthuswamyRIndependent regulation of chemokine responsiveness and cytolytic function versus CD8+ T cell expansion by dendritic cellsJ Immunol2010184259159720018619
   PubMed Web of Science ®Google Scholar
• MailliardRBSonYIRedlingerRDendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper functionJ Immunol200317152366237312928383
   PubMed Web of Science ®Google Scholar
• MailliardRBEgawaSCaiQComplementary dendritic cell-activating function of CD8+ and CD4+ T cells: helper role of CD8+ T cells in the development of T helper type 1 responsesJ Exp Med2002195447348311854360
   PubMed Web of Science ®Google Scholar
• BerkEKalinskiPLymphocyte-polarized DC1s: Effective inducers of tumor-specific CTLsOncoimmunology2012181443144423243623
   PubMed Web of Science ®Google Scholar
• BerkEMuthuswamyRKalinskiPLymphocyte-polarized dendritic cells are highly effective in inducing tumor-specific CTLsVaccine201230436216622422561311
   PubMed Web of Science ®Google Scholar
• MailliardRBWankowicz-KalinskaACaiQalpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activityCancer Res200464175934593715342370
   PubMed Web of Science ®Google Scholar
• VieiraPLde JongECWierengaEAKapsenbergMLKalinskiPDevelopment of Th1-inducing capacity in myeloid dendritic cells requires environmental instructionJ Immunol200016494507451210779751
   PubMed Web of Science ®Google Scholar
• WesaAKalinskiPKirkwoodJMTatsumiTStorkusWJPolarized type-1 dendritic cells (DC1) producing high levels of IL-12 family members rescue patient TH1-type antimelanoma CD4+ T cell responses in vitroJ Immunother2007301758217198085
   PubMed Web of Science ®Google Scholar
• RosesREXuSXuMKoldovskyUKoskiGCzernieckiBJDifferential production of IL-23 and IL-12 by myeloid-derived dendritic cells in response to TLR agonistsJ Immunol200818175120512718802116
   PubMed Web of Science ®Google Scholar
• PaustianCCaspellRJohnsonTEffect of multiple activation stimuli on the generation of Th1-polarizing dendritic cellsHum Immunol2011721243120951755
   PubMed Web of Science ®Google Scholar
• Ten BrinkeAKarstenMLDiekerMCZwagingaJJvan HamSMThe clinical grade maturation cocktail monophosphoryl lipid A plus IFNgamma generates monocyte-derived dendritic cells with the capacity to migrate and induce Th1 polarizationVaccine200725417145715217719152
   PubMed Web of Science ®Google Scholar
• Lopez-AlbaiteroAMailliardRHackmanTMaturation pathways of dendritic cells determine TAP1 and TAP2 levels and cross-presenting functionJ Immunother200932546547319609238
   PubMed Web of Science ®Google Scholar
• WieckowskiEChattaGSMailliardRMType-1 polarized dendritic cells loaded with apoptotic prostate cancer cells are potent inducers of CD8(+) T cells against prostate cancer cells and defined prostate cancer-specific epitopesProstate201171212513320717900
   PubMed Web of Science ®Google Scholar
• LeeJJFoonKAMailliardRBMuthuswamyRKalinskiPType 1- polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemiaJ Leukoc Biol200884131932518426971
   PubMed Web of Science ®Google Scholar
• MuthuswamyRMueller-BerghausJHaberkornUReinhartTASchadendorfDKalinskiPPGE(2) transiently enhances DC expression of CCR7 but inhibits the ability of DCs to produce CCL19 and attract naive T cellsBlood201011691454145920498301
   PubMed Web of Science ®Google Scholar
• MuthuswamyRUrbanJLeeJJReinhartTABartlettDKalinskiPAbility of mature dendritic cells to interact with regulatory T cells is imprinted during maturationCancer Res200868145972597818632653
   PubMed Web of Science ®Google Scholar
• GustafssonKIngelstenMBergqvistLNystromJAnderssonBKarlsson-ParraARecruitment and activation of natural killer cells in vitro by a human dendritic cell vaccineCancer Res200868145965597118632652
   PubMed Web of Science ®Google Scholar
• KunzMToksoyAGoebelerMEngelhardtEBrockerEGillitzerRStrong expression of the lymphoattractant C-X-C chemokine Mig is associated with heavy infiltration of T cells in human malignant melanomaJ Pathol1999189455255810629557
   PubMed Web of Science ®Google Scholar
• CalzasciaTMassonFDi Berardino-BessonWHoming phenotypes of tumor-specific CD8 T cells are predetermined at the tumor site by crosspresenting APCsImmunity200522217518415723806
   PubMed Web of Science ®Google Scholar
• WenzelJBekischBUerlichMHallerOBieberTTutingTType I interferon-associated recruitment of cytotoxic lymphocytes: a common mechanism in regressive melanocytic lesionsAm J Clin Pathol20051241374815923172
   PubMed Web of Science ®Google Scholar
• SalamaPPhillipsMGrieuFTumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancerJ Clin Oncol200927218619219064967
   PubMed Web of Science ®Google Scholar
• SenovillaLVacchelliEGalonJTrial watch: prognostic and predictive value of the immune infiltrate in cancerOncoimmunology2012181323134323243596
   PubMed Web of Science ®Google Scholar
• FridmanWHPagesFSautes-FridmanCGalonJThe immune contexture in human tumours: impact on clinical outcomeNat Rev Cancer201212429830622419253
   PubMed Web of Science ®Google Scholar
• GalonJCostesASanchez-CaboFType, density, and location of immune cells within human colorectal tumors predict clinical outcomeScience200631357951960196417008531
   PubMed Web of Science ®Google Scholar
• LazennecGRichmondAChemokines and chemokine receptors: new insights into cancer-related inflammationTrends Mol Med201016313314420163989
   PubMed Web of Science ®Google Scholar
• LeDTJaffeeEMRegulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspectiveCancer Res201272143439344422761338
   PubMed Web of Science ®Google Scholar
• ChuCSBoyerJSchulleryDSPhase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remissionCancer Immunol Immunother201261562964122021066
   PubMed Web of Science ®Google Scholar
• MorseMAHobeikaACOsadaTDepletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccinesBlood2008112361061818519811
   PubMed Web of Science ®Google Scholar
• JacobsJFPuntCJLesterhuisWJDendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patientsClin Cancer Res201016205067507820736326
   PubMed Web of Science ®Google Scholar
• IclozanCAntoniaSChiapporiAChenDTGabrilovichDTherapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancerCancer Immunol Immunther2013625909918
   PubMed Web of Science ®Google Scholar
• OuXCaiSLiuPEnhancement of dendritic cell-tumor fusion vaccine potency by indoleamine-pyrrole 2,3-dioxygenase inhibitor, 1-MTJ Cancer Res Clin Oncol2008134552553317909857
   PubMed Web of Science ®Google Scholar
• BasuGDTinderTLBradleyJMCyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDOJ Immunol200617742391240216888001
   PubMed Web of Science ®Google Scholar
• ZhangHTianMXiuCWangYTangGEnhancement of antitumor activity by combination of tumor lysate-pulsed dendritic cells and celecoxib in a rat glioma modelOncol Res2013201044745524308155
   PubMed Web of Science ®Google Scholar
• TakaokaKHidakaSHashitaniSEffect of a nitric oxide synthase inhibitor and a CXC chemokine receptor-4 antagonist on tumor growth and metastasis in a xenotransplanted mouse model of adenoid cystic carcinoma of the oral floorInt J Oncol201343373774523835861
   PubMed Web of Science ®Google Scholar
• SantegoetsSJTurksmaAWPowellDJJrHooijbergEde GruijlTDIL-21 in cancer immunotherapy: at the right place at the right timeOncoimmunology201326e2452223894713
   PubMed Web of Science ®Google Scholar
• PernaSKPagliaraDMahendravadaAInterleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibitionClin Cancer Res201420113113924097874
   PubMed Web of Science ®Google Scholar
• MackallCLFryTJGressREHarnessing the biology of IL-7 for therapeutic applicationNat Rev2011115330342
   Google Scholar
• RosenbergSASportesCAhmadzadehMIL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cellsJ Immunother200629331331916699374
   PubMed Web of Science ®Google Scholar
• WaldmannTAThe biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine designNat Rev Immunol20066859560116868550
   PubMed Web of Science ®Google Scholar
• SteelJCWaldmannTAMorrisJCInterleukin-15 biology and its therapeutic implications in cancerTrends Pharm Sci2012331354122032984
   PubMed Web of Science ®Google Scholar
• SkakKKraghMHausmanDSmythMJSivakumarPVInterleukin 21: combination strategies for cancer therapyNat Rev Drug Discov20087323124018259184
   PubMed Web of Science ®Google Scholar
• FrederiksenKSLundsgaardDFreemanJAIL-21 induces in vivo immune activation of NK cells and CD8(+) T cells in patients with metastatic melanoma and renal cell carcinomaCancer Immunol Immunother200857101439144918286285
   PubMed Web of Science ®Google Scholar
• PetrellaTMTozerRBelangerKInterleukin-21 has activity in patients with metastatic melanoma: a phase II studyJ Clin Oncol201230273396340122915661
   PubMed Web of Science ®Google Scholar
• ThompsonJACurtiBDRedmanBGPhase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinomaJ Clin Oncol200826122034203918347008
   PubMed Web of Science ®Google Scholar
• SchmidtHBrownJMouritzenUSafety and clinical effect of subcutaneous human interleukin-21 in patients with metastatic melanoma or renal cell carcinoma: a phase I trialClin Cancer Res201016215312531920959407
   PubMed Web of Science ®Google Scholar
• HashmiMHVan VeldhuizenPJInterleukin-21: updated review of Phase I and II clinical trials in metastatic renal cell carcinoma, metastatic melanoma and relapsed/refractory indolent non-Hodgkin’s lymphomaExpert Opin Biol Ther201010580781720384523
   PubMed Web of Science ®Google Scholar
• MurugaiyanGSahaBIL-27 in tumor immunity and immunotherapyTrends Mol Med201319210811623306374
   PubMed Web of Science ®Google Scholar
• SwarbrickAJunankarSRBattenMCould the properties of IL-27 make it an ideal adjuvant for anticancer immunotherapy?Oncoimmunology201328e2540924083081
   PubMed Web of Science ®Google Scholar
• WadaSJacksonCMYoshimuraKSequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancerJ Transl Med2013118923557194
   PubMed Web of Science ®Google Scholar
• LeDTLutzEUramJNEvaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancerJ Immunother201336738238923924790
   PubMed Web of Science ®Google Scholar
• MadanRAMohebtashMArlenPMIpilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trialLancet Oncol201213550150822326924
   PubMed Web of Science ®Google Scholar
• RibasAComin-AnduixBChmielowskiBDendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanomaClin Cancer Res200915196267627619789309
   PubMed Web of Science ®Google Scholar
• PardollDMThe blockade of immune checkpoints in cancer immunotherapyNat Rev Cancer201212425226422437870
   PubMed Web of Science ®Google Scholar
• BrahmerJRDrakeCGWollnerIPhase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlatesJ Clin Oncol201028193167317520516446
   PubMed Web of Science ®Google Scholar
• BrahmerJRTykodiSSChowLQSafety and activity of anti-PD-L1 antibody in patients with advanced cancerN Engl J Med2012366262455246522658128
   PubMed Web of Science ®Google Scholar
• LipsonEJSharfmanWHDrakeCGDurable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibodyClin Cancer Res201319246246823169436
   PubMed Web of Science ®Google Scholar
• SierroSRDondaAPerretRCombination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunityEur J Immunol20114182217222821538347
   PubMed Web of Science ®Google Scholar
• RosenblattJGlotzbeckerBMillsHPD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccineJ Immunother201134540941821577144
   PubMed Web of Science ®Google Scholar
• LiBVanRoeyMWangCChenTHKormanAJoossKAnti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor- secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumorsClin Cancer Res20091551623163419208793
   PubMed Web of Science ®Google Scholar
• DuraiswamyJKaluzaKMFreemanGJCoukosGDual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumorsCancer Res201373123591360323633484
   PubMed Web of Science ®Google Scholar
• WeberJSKudchadkarRRGibneyGTPhase I/II trial of PD-1 antibody nivolumab with peptide vaccine in patients naive to or that failed ipilimumabJ Clin Oncol201331Suppl 15 Abstr 9011
   Google Scholar
• MkrtichyanMNajjarYGRaulfsECAnti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanismsEur J Immunol201141102977298621710477
   PubMed Web of Science ®Google Scholar